Inhibrx Biosciences, Inc. INBX Short- and long-term operating lease liabilities

Short- and long-term operating lease liabilities at other companies

Oruka Therapeutics, Inc.ORKA

-$125K-495%

Rumble, Inc.RUM

-$337.78K-40.4%

Mission Produce, Inc.AVO

-$2.8M-3.7%

The Baldwin Insurance Group, Inc.BWIN

-$4.74M-16.2%

NextNavNN

$77K-63.7%

Target HospitalityTH

-$2.3M-33.9%

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s short- and long-term operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s short- and long-term operating lease liabilities?: Inhibrx Biosciences, Inc. (INBX) reported short- and long-term operating lease liabilities of -$549K in Q1 2026.
How has Inhibrx Biosciences, Inc.'s short- and long-term operating lease liabilities changed year-over-year?: Inhibrx Biosciences, Inc.'s short- and long-term operating lease liabilities decreased by 221.1% year-over-year, from -$171K to -$549K.